PURPOSE: Self-expanding fully covered metal stents (CSs) are ideal for use in benign esophagogastric disease. We reviewed our experience with CS to evaluate outcomes, to determine a role for CS in a standard treatment for benign esophageal conditions, and to compare our results with recently published studies. METHODS: We performed a retrospective chart review from 2005 to 2012. RESULTS: A total of 57 CSs were placed in 44 patients. Indications were stricture (11 patients), anastomotic leak (20), perforation (7), and tracheoesophageal fistulae (6). For GI tract disruptions, open repair or diversion was avoided in 31/33 patients (93.9 %) but required an associated drainage procedure in 22/33 (67 %) patients. Resolution does not depend on achieving radiological control with 6/26 (23 %) having evidence of a persistent leak. Benign strictures were dilated at a mean of 3.7 times prior to stenting. Adjunctive intra-mucosal steroid injections were used in 8/11 patients. Stents were removed at a mean of 33 days. At a mean of 283 days of follow-up, 6/11 (54.5 %) had symptom resolution. The most common complication was stent migration occurring in 17.5 % of patients overall. CONCLUSION: Covered stents are an effective adjunct in the management of benign upper gastrointestinal tract fistulae, leaks, perforations and benign strictures.
PURPOSE: Self-expanding fully covered metal stents (CSs) are ideal for use in benign esophagogastric disease. We reviewed our experience with CS to evaluate outcomes, to determine a role for CS in a standard treatment for benign esophageal conditions, and to compare our results with recently published studies. METHODS: We performed a retrospective chart review from 2005 to 2012. RESULTS: A total of 57 CSs were placed in 44 patients. Indications were stricture (11 patients), anastomotic leak (20), perforation (7), and tracheoesophageal fistulae (6). For GI tract disruptions, open repair or diversion was avoided in 31/33 patients (93.9 %) but required an associated drainage procedure in 22/33 (67 %) patients. Resolution does not depend on achieving radiological control with 6/26 (23 %) having evidence of a persistent leak. Benign strictures were dilated at a mean of 3.7 times prior to stenting. Adjunctive intra-mucosal steroid injections were used in 8/11 patients. Stents were removed at a mean of 33 days. At a mean of 283 days of follow-up, 6/11 (54.5 %) had symptom resolution. The most common complication was stent migration occurring in 17.5 % of patients overall. CONCLUSION: Covered stents are an effective adjunct in the management of benign upper gastrointestinal tract fistulae, leaks, perforations and benign strictures.
Authors: Mohamad A Eloubeidi; Jayant P Talreja; Tercio L Lopes; Basil S Al-Awabdy; Vanessa M Shami; Michel Kahaleh Journal: Gastrointest Endosc Date: 2011-01-26 Impact factor: 9.427
Authors: Jack I Ramage; Ashwin Rumalla; Todd H Baron; Nicole L Pochron; Alan R Zinsmeister; Joseph A Murray; Ian D Norton; Nancy Diehl; Yvonne Romero Journal: Am J Gastroenterol Date: 2005-11 Impact factor: 10.864
Authors: Jonathan D'Cunha; Natasha M Rueth; Shawn S Groth; Michael A Maddaus; Rafael S Andrade Journal: J Thorac Cardiovasc Surg Date: 2011-07 Impact factor: 5.209
Authors: Andreas Fischer; Oliver Thomusch; Stefan Benz; Ernst von Dobschuetz; Peter Baier; Ulrich T Hopt Journal: Ann Thorac Surg Date: 2006-02 Impact factor: 4.330